Carbamazepine and its 10,11-epoxide metabolite in acute mania: clinical and pharmacokinetic correlates

@article{Petit1991CarbamazepineAI,
  title={Carbamazepine and its 10,11-epoxide metabolite in acute mania: clinical and pharmacokinetic correlates},
  author={Pierre Petit and R. Lonjon and Maryl{\`e}ne Cociglio and A. Sluzewska and Jean Pierre Blayac and Bernard Hue and Robert Alric and R. Pouget},
  journal={European Journal of Clinical Pharmacology},
  year={1991},
  volume={41},
  pages={541-546}
}
The study was designed to investigate the antimanic profile of carbamazepine as a first-line drug in affective or schizoaffective disorders, to correlate the clinical efficacy with the plasma level of carbamazepine and its 10,11-epoxide metabolite, and to test the potential value of monitoring the salivary level. It was administered alone for 3 weeks to 21 acute manic inpatients. During the first week, the dosage was rapidly increased to 800 mg/day in order to produce steady-state plasma levels… CONTINUE READING